



CERTIFICATE OF MAILING

I hereby certify that on July 23, 2001, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.

37 C.F.R. § 1.8(a)

☒ with sufficient postage as first class mail

37 C.F.R. § 1.10

☐ as "Express Mail Post Office to Addressee" Mailing Label No.

Mamie Managan
Mamie Managan

Applicant:

Schor et al.

Serial No.: 09/581,651

Filed: October 10, 2000

Title: POLYPEPTIDES,
POLYNUCLEOTIDES AND
USES THEREOF

Examiner: Rawlings, S

Group Art Unit: 1642

Atty. Docket No.: 350013-72

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL SHEET

Commissioner for Patents
Washington, D.C. 20231

Sir:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8(a).
- ☒ Response to Office Action dated June 21, 2001.
- ☒ Computer Readable Sequence Listing.
- ☒ Substantially Similar Copy of Specification as Filed.
- ☒ Return postcard.
- ☒ Sequence Listing.

Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230. A duplicate of this sheet is enclosed.

Dated: July 23, 2001

Guy Porter Smith
Guy Porter Smith
Registration No. 20,142

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East, 38th Floor
Los Angeles, California 90067
Phone: 310.788.5000
Fax: 310.788.5100

DISK TO STIC

DATE:



Serial No. 09/581,651




Docket No. 350013-72

RECEIVED

JUL 31 2001

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited on July 23, 2001 with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231


Mamie Managan

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	:	Group Art Unit: 1642
	:	
Schor, Seth, Lawrence et. al.	:	Examiner: Rawlings, S
	:	
Title: Polypeptides, Polynucleotides and Uses Thereof	:	
	:	
Serial No.: 09/581,651	:	
	:	
Filed: October 10, 2000	:	

RESPONSE TO OFFICE ACTION DATED JUNE 21, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find in this response a substantially similar copy of the specification as filed. The only changes that have been made are the assignments of sequence identification numbers [SEQ ID] to the sequences disclosed in the specification as filed. No new matter has been added.

Please find enclosed a separate paper printout of the Sequence Listing as well as floppy disk having the Sequence Listing in a computer readable format, in compliance with the requirements of 37 CFR 1.821-1.825. The sequence listing information recorded in computer readable form is identical to the paper sequence listing.

In addition, the appropriate SEQ ID number has been included in Fig. 1.


Please note that the amino acid sequences disclosed in the specification as filed, are listed by their one letter symbols, whereas the amino acids in the attached Sequence Listing, in both paper and computer readable forms, are listed utilizing their 3-letter symbols, in compliance with 37 CFR 1.822. The composition of the sequences in both the printed and computer readable format Sequence Listing are identical to those originally filed and as previously stated, no new matter has been added.

Any additional fees required in connection with this communication which are not specifically provided for herewith are authorized to be charged to the Deposit Account No. 16-2230 in the name of Oppenheimer Wolff & Donnelly LLP. Any overpayments are also authorized to be credited to this account. A return postcard and this Transmittal Letter in duplicate are attached.

Respectfully submitted,

July 23, 2001

By



Guy Porter Smith

Reg. 20,142

Attorney for Applicant

Attachments: Sequence Listing

Copy of Specification with SEQ ID numbers added.

Copy of Notice

OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, 38th Floor

Los Angeles, CA 90067-3024

Telephone: (310) 788-5000

Facsimile: (310) 788-5100

Notice to Comply



Application No.

09/581,651

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)

SCHOR ET AL.

Art Unit

1642

TECH CENTER 1600 2900

JUL 31 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



RECEIVED
JUL 31 2001
TECH CENTER 1600/2900

Attachment for PTO-948 (Rev. 03/01, or earlier)
6/18/01

The below text replaces the pre-printed text under the heading, "Information on How to Effect Drawing Changes," on the back of the PTO-948 (Rev. 03/01, or earlier) form.

INFORMATION ON HOW TO EFFECT DRAWING CHANGES

1. Correction of Informalities -- 37 CFR 1.85

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the Notice of Allowability. Extensions of time may NOT be obtained under the provisions of 37 CFR 1.136(a) or (b) for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

2. Corrections other than Informalities Noted by Draftsperson on form PTO-948.

All changes to the drawings, other than informalities noted by the Draftsperson, **MUST** be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings **MUST** be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

Timing of Corrections

Applicant is required to submit the drawing corrections within the time period set in the attached Office communication. See 37 CFR 1.85(a).

Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.